Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Med Chem ; 50(5): 984-1000, 2007 Mar 08.
Artículo en Inglés | MEDLINE | ID: mdl-17274610

RESUMEN

Compounds that simultaneously activate the three peroxisome proliferator-activated receptor (PPAR) subtypes alpha, gamma, and delta hold potential to address the adverse metabolic and cardiovascular conditions associated with diabetes and the metabolic syndrome. We recently identified the indanylacetic acid moiety as a well-tunable PPAR agonist head group. Here we report the synthesis and structure-activity relationship (SAR) studies of novel aryl tail group derivatives that led to a new class of potent PPAR pan agonists. While most of the tail group modifications imparted potent PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction of new heterocyclic substituents that were not known in the PPAR literature. Systematic optimization led to the discovery of 4-thiazolyl-phenyl derivatives with potent PPAR alpha/gamma/delta pan agonistic activity. The lead candidate from this series was found to exhibit excellent ADME properties and superior therapeutic potential compared to known PPAR gamma activating agents by favorably modulating lipid levels in hApoA1 mice and hyperlipidemic hamsters, while normalizing glucose levels in diabetic rodent models.


Asunto(s)
Acetatos/síntesis química , Hipoglucemiantes/síntesis química , Indanos/síntesis química , PPAR alfa/agonistas , PPAR delta/agonistas , PPAR gamma/agonistas , Triazoles/síntesis química , Acetatos/química , Acetatos/farmacología , Animales , Apolipoproteína A-I/genética , Línea Celular , Cricetinae , Femenino , Humanos , Hiperlipidemias/tratamiento farmacológico , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Técnicas In Vitro , Indanos/química , Indanos/farmacología , Lípidos/sangre , Masculino , Ratones , Ratones Transgénicos , PPAR alfa/genética , PPAR gamma/genética , Ensayo de Unión Radioligante , Ratas , Ratas Zucker , Solubilidad , Estereoisomerismo , Relación Estructura-Actividad , Activación Transcripcional , Triazoles/química , Triazoles/farmacología
2.
Bioorg Med Chem Lett ; 17(4): 1056-61, 2007 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17157013

RESUMEN

Modulation of PPAR activities represents an attractive approach for the treatment of diabetes with associated cardiovascular complications. The indanylacetic acid structural motif has proven useful in the generation of potent and tunable PPAR ligands. Modification of the substituents on the linker and the heterocycle tail group allowed for the modulation of the selectivity at the different receptor subtypes. Compound 33 was evaluated in vivo, where it displayed the desired reduction of glucose levels and increase in HDL levels in various animal models.


Asunto(s)
Acetatos/síntesis química , Acetatos/farmacología , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacología , Indanos/síntesis química , Indanos/farmacología , PPAR alfa/agonistas , PPAR delta/agonistas , PPAR gamma/agonistas , Animales , Área Bajo la Curva , Glucemia/metabolismo , Células Cultivadas , Colesterol/sangre , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/genética , Relación Dosis-Respuesta a Droga , Humanos , Hidrólisis , Hipoglucemiantes/farmacocinética , Indicadores y Reactivos , Lipoproteínas HDL/sangre , Ratones , Ratas , Ratas Zucker , Rosiglitazona , Relación Estructura-Actividad , Tiazolidinedionas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA